A Phase II study of Gemcitabine, Cisplatin and Bevacizumab for the patients with first recurrent and refractory ovarian clear cell carcinoma
- Conditions
- The first-time recurrence/relapse of ovarian cell carcinoma.
- Registration Number
- JPRN-UMIN000051087
- Lead Sponsor
- Kansai Clinical Oncology Group(KCOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 28
Not provided
1)Patients with contraindications to Gemcitabine, Cisplatin or Bevacizumab 2)Patients with uncontrolled heart disease, renal disease, or diabetes 3) Patients with interstitial pneumonia or pulmonary fibrosis (confirmed by CT examination) 4)Patients with intestinal paralysis or intestinal obstruction 5) Patients with infectious diseases requiring treatment 6)Patients who have received radiotherapy to the chest or abdomen 7) Patients with active double cancer (not including carcinoma in situ) 8)Patients with a history of severe drug hypersensitivity 9) Patients with a history of underlying disease associated with obstructive bowel disease including subileus, patients with diverticulum, intestinal fistula, gastrointestinal perforation, intra-abdominal abscess, obvious rectosigmoid colon invasion by pelvic examination, CT examination Patients with clinical symptoms of obvious intestinal infiltration or intestinal obstruction due to 10)Patients with symptomatic central nervous system metastases 11)Patients who are pregnant or breastfeeding, or who may become pregnant during the treatment period of this protocol and are not willing to use contraception 12)Patients with the following diseases 13)Patients who are currently or recently (within 30 days prior to the start of this protocol treatment) receiving or receiving other investigational drugs (including unapproved drugs). 14)Patients who are judged inappropriate for participation in this study by investigators or subinvestigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method